CDC chooses BioReference as one of the antibody testing and service providers for national serological survey ELMWOOD PARK, N.J., July 20, 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced it will accept an Indefinite Delivery Indefinite Quantity (IDIQ) contract award to provide Commercial Surge Capacity Testing for COVID-19 Emergency Response to the […]
Search Results for: ACT 1 test
PR Newswire Transaction to extend Labcorp’s leadership in oncology and expand access to the company’s high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI, March 11, 2025 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference […]
06
Feb
Feb
As we come together to recognize World Cancer Day in February 2024, it’s important to acknowledge the significant strides being made in cancer care. (123) BioReference continues to be at the forefront of these efforts, demonstrating a steadfast commitment to advancing oncology testing, tailored precision medicine, collaborative care and support, advancements in cancer research, and […]
Press Release
BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing
28
Nov
Nov
Elmwood Park, NJ – November 28, 2023 – BioReference® Health, LLC (BRH), a leading specialty laboratory in the United States, announced a strategic collaboration with Prognos Health, a pioneer in providing accessible, quality real world data (“RWD”) for the pharmaceutical and life science industries. This collaborative arrangement will offer healthcare providers and researchers unique solutions […]
27
Nov
Nov
Lung and bronchus cancer represents more than one eighth of all new cancer cases in the US and is the leading cause of cancer deaths worldwide, according to the World Health Organization. As we wrap up on National Lung Cancer Awareness Month this November, we aim to empower patients to take more control of their […]
14
Nov
Nov
Grow it Out in Honor of Men’s Health throughout No Shave November, and talk to your healthcare provider about early detection screenings for Prostate Cancer like the 4Kscore Test from OPKO, BioReference and GenPath.
Press Release
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
07
Nov
Nov
World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country BOSTON, MA, ELMWOOD PARK, NJ, and Rolle, Switzerland, November 7, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that BioReference® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that […]
09
May
May
National Women’s Health Week is an annual initiative driven by the U.S. Department of Health and Human Services that aims to raise awareness and encourage women to make their health a priority. While finding the time and resources to properly manage one’s health may feel overwhelming, there are many actionable ways women can take to […]
05
May
May
Overall, more than 60 million Americans suffer from asthma and allergies according to the Asthma and Allergy Foundation of America (AAFA) and allergic asthma is the most common type. Each allergy season is all too familiar for those with allergies. With each bloom and breeze, all the common signs and symptoms emerge that can include […]
Press Release
BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings
09
Feb
Feb
CINtec® PLUS Cytology offered as a reflex test when cytology is NILM and HPV positive ELMWOOD PARK, NJ, February 9, 2023 – BioReference® Health LLC, one of the largest full-service specialty laboratories in the United States, announced today it will be one of the first commercial laboratories to use offer the CINtec® PLUS Cytology test from […]
